STOCK TITAN

InMed Pharmaceuticals Inc - INM STOCK NEWS

Welcome to our dedicated news page for InMed Pharmaceuticals (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on InMed Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect InMed Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of InMed Pharmaceuticals's position in the market.

Rhea-AI Summary
InMed Pharmaceuticals announced safety and efficacy results from its Phase 2 clinical trial for the treatment of symptoms related to EB. The trial showed positive indication of enhanced anti-itch activity for INM-755 CBN cream. InMed will pursue strategic partnership opportunities for INM-755 in EB and other itch-related skin conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.56%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals announced results from a neurodegenerative disease study, demonstrating the potential of a specific rare cannabinoid to reduce amyloid toxicity and tau protein expression while enhancing neuronal cell growth. This could be a significant development in the treatment of neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) announces participation in upcoming virtual investor events. CEO Eric A. Adams and VP Jerry Griffin will co-host a presentation on addressing the increasing demand for rare cannabinoids. Investors can register for the Tribe Public Webinar on May 31 and the Investor Summit on June 1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.09%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
management
InMed Pharmaceuticals Inc

Nasdaq:INM

INM Rankings

INM Stock Data

2.00M
4.84M
1.36%
13.29%
0.17%
Research and Development in Biotechnology (except Nanobiotechnology)
Professional, Scientific, and Technical Services
Link
Canada
Vancouver

About INM

inmed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. inmed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.